NASD · Healthcare · Drug Manufacturers - Specialty & Generic · China
BGM Group Ltd is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the BGM Group Ltd stock.
Overvalued: intrinsic value $1.43 per share, market price $8.09, margin of safety -467.2% (as of 2026-10-30).
Its through-the-cycle earnings (3.2% median margin), capitalised at 13.1% with no growth, values the shares at $1.43; the price of $8.09 is 467% above that value.
Leak Score: 14/100 on 8 of 12 signals (On Watch).
All 84 Drug Manufacturers - Specialty & Generic stocks
32 more in this industry show a wider margin of safety.
BGM is overvalued (as of the 2026-10-30 close). Its through-the-cycle earnings (3.2% median margin), capitalised at 13.1% with no growth, values the shares at $1.43; the price of $8.09 is 467% above that value.
$1.43 per share (as of the 2026-10-30 close), against a market price of $8.09. That is a margin of safety of -467.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
14 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.